Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-us...

Descripción completa

Detalles Bibliográficos
Autores principales: Vannucchi, Alessandro M., Sordi, Benedetta, Morettini, Alessandro, Nozzoli, Carlo, Poggesi, Loredana, Pieralli, Filippo, Bartoloni, Alessandro, Atanasio, Alessandro, Miselli, Filippo, Paoli, Chiara, Loscocco, Giuseppe G., Fanelli, Andrea, Para, Ombretta, Berni, Andrea, Tassinari, Irene, Zammarchi, Lorenzo, Maggi, Laura, Mazzoni, Alessio, Scotti, Valentina, Falchetti, Giorgia, Malandrino, Danilo, Luise, Fabio, Millotti, Giovanni, Bencini, Sara, Capone, Manuela, Piccinni, Marie Pierre, Annunziato, Francesco, Guglielmelli, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437386/
https://www.ncbi.nlm.nih.gov/pubmed/32814839
http://dx.doi.org/10.1038/s41375-020-01018-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437386/
https://www.ncbi.nlm.nih.gov/pubmed/32814839
http://dx.doi.org/10.1038/s41375-020-01018-y

Ejemplares similares